HIT Consultant – Read More
, we are setting the new standard of colonoscopy, and saving more and more lives.What You Should Know:
– MAGENTIQ EYE LTD., an innovator in AI-powered gastroenterology decision-support software, announced completion of its Series A funding round led by aMoon, with participation from existing investors Norgine Ventures BV (Netherlands), Nina Capital (EU & USA), Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA).
The proceeds from the funding round will support the continued development and expansion of MAGENTIQ EYE’s diagnostic tools, in addition to driving commercial growth in the USA, Europe, and globally. The company plans to use direct sales and partnerships with industry leaders to achieve this growth.
Enhancing Polyp Detection and Clinical Insights
MAGENTIQ EYE’s FDA- and CE-approved software, MAGENTIQ-COLO, is designed to enhance polyp detection and analysis capabilities during colonoscopies. The software significantly improves adenoma detection rates and offers real-time insights. The CE-approved version of MAGENTIQ-COLO also includes polyp-size category and type estimation, as well as advanced AI-generated reports.
According to Roy Wiesner, a partner at aMoon who will be joining the board of directors, MAGENTIQ’s solution stands out as the most accurate on the market, offering the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications.
The company is currently in clinical trials for diagnostic tools targeting specialized diseases in the lower and upper gastrointestinal tract, such as ulcerative colitis, early dysplasia in Barrett’s esophagus, and gastric intestinal metaplasia. It is also developing automated quality indicators for GI procedures.
“This investment round marks a major milestone for MAGENTIQ EYE. We are thrilled to welcome aMoon and Roy Wiesner to our journey,” said Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE. “With aMoon’s support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the U.S. and Europe, and bring our advanced diagnostic tools to more physicians and patients around the world.”
